Once-a-Day Oral Treatment Against COVID-19 Disease Launches Phase 2 Study

Montreal based Laurent Pharmaceuticals Inc. announced on August 27, 2020, that it has received approval from the U.S. FDA to start enrolling patients in Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential treatment against COVID-19 disease. LAU-7b has shown potent antiviral effects in-vitro against both SARS-CoV-2 and MERS-CoV coronaviruses.

“The main objective of this study is to demonstrate that LAU-7b is a safe and effective treatment option for COVID-19 patients that are at risk of lung complications because of their age, underlying condition, or both,” stated Dr. Radu Pislariu, CEO of Laurent Pharmaceuticals.